Nutcracker Therapeutics Raises $167 Million In Series C Financing To Advance Its Mrna Therapeutics And First-Of-Its-Kind Biochip-Based Manufacturing Platform
Nutcracker Therapeutics Raises $167 Million In Series C Financing To Advance Its Mrna Therapeutics And First-Of-Its-Kind Biochip-Based Manufacturing Platform
03/14/22, 12:00 PM
Money raised
$167 million
Round Type
series c
Nutcracker Therapeutics, Inc., a biotech company developing RNA therapeutics using its proprietary biochip-based manufacturing platform, today announced it has raised $167 million in Series C financing led by ARCH Venture Partners. The funds will allow the company to expand and advance its pipeline of mRNA medicines for cancer, in addition to further refining its RNA manufacturing platform and the underlying technology.
Company Info
Additional Info
Nutcracker Therapeutics is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA therapeutics platform. Armed with this high-tech advantage, we have developed a wholly owned pipeline of RNA therapeutic programs and established partnership initiatives with top clinical investigators at several leading institutions across the globe. With our platform's ability to accelerate the development of life-changing RNA therapeutics, we seek to advance breakthrough RNA therapies at high velocity through all stages of development across a variety of indications. Our technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in capacity scaling and point-of-care delivery over other RNA manufacturing approaches.